Benzinga | Mar 22, 2021 08:22AM EDT

Akers Biosciences Announces Shareholder Meeting For April 15 At 10 a.m. To Vote On Business Combination With MyMD Pharmaceuticals

Akers Biosciences, Inc (NASDAQ:AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting") to vote on the proposed business combination with MyMD Pharmaceuticals ("MyMD"). The meeting will be held on April 15, 2021 at 10:00 a.m., Eastern Time, and will be "virtual," meaning that you can participate in the meeting online at www.virtualshareholdermeeting.com/AKER2021SM.

In connection with the Meeting, Akers' board of directors has fixed the close of business on March 15, 2021 as the record date for the special meeting.

"We believe the strategic combination of Akers with MyMD has the potential to accelerate the commercialization of MyMD's drug development platform, which has been built over the past seven years," said Chris Schreiber, Chief Executive Officer of Akers Biosciences, "MYMD-1 is targeting the underlying causes of chronic autoimmune diseases as well as aging itself, and SUPERA-1R--a patent-protected synthetic derivative of cannabidiol (CBD)--targeting numerous key cannabinoid receptors to address pain, anxiety, sleep disorders, and seizures. We look forward to closing the proposed business combination as soon as possible following the Meeting and will update shareholders at that time."